|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ni Y, Ye X, Yang X, Huang G, Li W, Wang J,
Han X, Wei Z, Meng M and Zou Z: Microwave ablation for non-small
cell lung cancer with synchronous solitary extracranial metastasis.
J Cancer Res Clin Oncol. 146:1361–1367. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakahara Y, Hosomi Y, Shibuya M, Mitsufuji
H, Katagiri M, Naoki K, Soejima K, Nogami N, Nagase S, Nishikawa M,
et al: Multicenter study of zoledronic acid administration in
non-small-cell lung cancer patients with bone metastasis: Thoracic
oncology research group (TORG) 1017. Mol Clin Oncol. 11:349–353.
2019.PubMed/NCBI
|
|
5
|
Oster G, Lamerato L, Glass AG, Richert-Boe
KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran
A and Edelsberg J: Natural history of skeletal-related events in
patients with breast, lung, or prostate cancer and metastases to
bone: A 15-year study in two large US health systems. Support Care
Cancer. 21:3279–3286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Katakami N, Kunikane H, Takeda K, Takayama
K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, et al:
Prospective study on the incidence of bone metastasis (BM) and
skeletal-related events (SREs) in patients (pts) with stage IIIB
and IV lung cancer-CSP-HOR 13. J Thorac Oncol. 9:231–238. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang L and Gong Z: Clinical
characteristics and prognostic factors in bone metastases from lung
cancer. Med Sci Monit. 23:4087–4094. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lang J, Zhao Q, He Y and Yu X: Bone
turnover markers and novel biomarkers in lung cancer bone
metastases. Biomarkers. 23:518–526. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pontarollo G, Confavreux CB, Pialat JB,
Isaac S, Forest F, Yvorel V, Maury JM, Girard N and Brevet M: Bone
decalcification to assess programmed cell death ligand 1 expression
in bone metastases of non-small cell lung cancers. J Bone Oncol.
21:1002752020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao H, Han KL, Wang ZY, Chen Y, Li HT,
Zeng JL, Shen Z and Yao Y: Value of C-telopeptide-cross-linked Type
I collagen, osteocalcin, bone-specific alkaline phosphatase and
procollagen Type I N-terminal propeptide in the diagnosis and
prognosis of bone metastasis in patients with malignant tumors. Med
Sci Monit. 17:CR626–CR633. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang S, Liu Y, Li MY, Ng CSH, Yang SL,
Wang S, Zou C, Dong Y, Du J, Long X, et al: FOXP3 promotes tumor
growth and metastasis by activating Wnt/β-catenin signaling pathway
and EMT in non-small cell lung cancer. Mol Cancer. 16:1242017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei CH, Wu G, Cai Q, Gao XC, Tong F, Zhou
R, Zhang RG, Dong JH, Hu Y and Dong XR: MicroRNA-330-3p promotes
cell invasion and metastasis in non-small cell lung cancer through
GRIA3 by activating MAPK/ERK signaling pathway. J Hematol Oncol.
10:1252017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuan J, Zhang G, Li X, Ma Q, Cheng W, Wang
W, Zhang B, Hu T and Song G: Knocking down USP39 inhibits the
growth and metastasis of non-small-cell lung cancer cells through
activating the p53 pathway. Int J Mol Sci. 21:89492020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ge L, Shao GR, Wang HJ, Song SL, Xin G, Wu
M and Zhang FX: Integrated analysis of gene expression profile and
genetic variations associated with ovarian cancer. Eur Rev Med
Pharmacol Sci. 19:2703–2710. 2015.PubMed/NCBI
|
|
15
|
Shi WY, Liu KD, Xu SG, Zhang JT, Yu LL, Xu
KQ and Zhang TF: Gene expression analysis of lung cancer. Eur Rev
Med Pharmacol Sci. 18:217–228. 2014.PubMed/NCBI
|
|
16
|
Liao Y, Yin G, Wang X, Zhong P, Fan X and
Huang C: Identification of candidate genes associated with the
pathogenesis of small cell lung cancer via integrated
bioinformatics analysis. Oncol Lett. 18:3723–3733. 2019.PubMed/NCBI
|
|
17
|
Ritchie ME, Belinda P, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Püffeld M, Seiler C, Kuhlmann M,
Sreenivasulu N and Butardo VM Jr: Analysis of developing rice grain
transcriptome using the agilent microarray platform. Methods Mol
Biol. 1892:277–300. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eadie A, Vásquez I, Liang X, Wang X,
Souders CL II, Chehouri JE, Hoskote R, Feswick A, Cowie AM,
Loughery JR and Martyniuk CJ: Transcriptome network data in larval
zebrafish (Danio rerio) following exposure to the
phenylpyrazole fipronil. Data Brief. 33:1064132020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bolstad BM, Irizarry RA, Astrand M and
Speed TP: A comparison of normalization methods for high density
oligonucleotide array data based on variance and bias.
Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Groth D, Hartmann S, Klie S and Selbig J:
Principal components analysis. Methods Mol Biol. 930:527–547. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li O, Tormin A, Sundberg B, Hyllner J, Le
Blanc K and Scheding S: Human embryonic stem cell-derived
mesenchymal stroma cells (hES-MSCs) engraft in vivo and support
hematopoiesis without suppressing immune function: Implications for
off-the shelf ES-MSC therapies. PLoS One. 8:e553192013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liao S, Yang Y, Chen S, Bi Y, Huang Q, Wei
Z, Qin A and Liu B: IL-24 inhibits endometrial cancer cell
proliferation by promoting apoptosis through the mitochondrial
intrinsic signaling pathway. Biomed Pharmacother. 124:1098312020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng Y, Wang Q, Li T, Qian J, Lu Y, Li Y,
Bi E, Reu F, Qin Y, Drazba J, et al: Role of myeloma-derived MIF in
myeloma cell adhesion to bone marrow and chemotherapy response. J
Natl Cancer Inst. 108:djw1312016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rotow J and Bivona TG: Understanding and
targeting resistance mechanisms in NSCLC. Nat Rev Cancer.
17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hui W, Yan Z, Hui Z and Yu J: Risk factors
for bone metastasis in completely resected non-small-cell lung
cancer. Future Oncol. 13:695–704. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang XY, Liao JJ and Xue WR: FMNL1
down-regulation suppresses bone metastasis through reducing TGF-β1
expression in non-small cell lung cancer (NSCLC). Biomed
Pharmacother. 117:1091262019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen L, Zhang YH, Lu G, Huang T and Cai
YD: Analysis of cancer-related lncRNAs using gene ontology and KEGG
pathways. Artif Intell Med. 76:27–36. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ding J and Zhang Y: Analysis of key GO
terms and KEGG pathways associated with carcinogenic chemicals.
Comb Chem High Throughput Screen. Dec 18–2017.(Online ahead of
print).
|
|
32
|
Wang R, Yin C, Fu L, Liu J, Li J and Yin
L: Expression profile analysis for epithelial-mesenchymal
transition of breast cancer cell line DKTA based on microarray
data. Eur J GynaecolOncol. 40:579–584. 2019.
|
|
33
|
Fujita A, Sato JR, Festa F, Gomes LR,
Oba-Shinjo SM, Marie SK, Ferreira CE and Sogayar MC: Identification
of COL6A1 as a differentially expressed gene in human astrocytomas.
Genet Mol Res. 7:371–378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Owusu-Ansah KG, Song G, Chen R, Edoo MIA,
Li J, Chen B, Wu J, Zhou L, Xie H, Jiang D and Zheng S: COL6A1
promotes metastasis and predicts poor prognosis in patients with
pancreatic cancer. Int J Oncol. 55:391–404. 2019.PubMed/NCBI
|
|
35
|
Zhu YP, Wan FN, Shen YJ, Wang HK, Zhang GM
and Ye DW: Reactive stroma component COL6A1 is upregulated in
castration-resistant prostate cancer and promotes tumor growth.
Oncotarget. 6:14488–14496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hou T, Tong C, Kazobinka G, Zhang W, Huang
X, Huang Y and Zhang Y: Expression of COL6A1 predicts prognosis in
cervical cancer patients. Am J Transl Res. 8:2838–2844.
2016.PubMed/NCBI
|
|
37
|
Wan F, Wang H, Shen Y, Zhang H, Shi G, Zhu
Y, Dai B and Ye D: Upregulation of COL6A1 is predictive of poor
prognosis in clear cell renal cell carcinoma patients. Oncotarget.
6:27378–27387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Frka K, Facchinello N, Del Vecchio C,
Carpi A, Curtarello M, Venerando R, Angelin A, Parolin C, Bernardi
P, Bonaldo P, et al: Lentiviral-mediated RNAi in vivo silencing of
Col6a1, a gene with complex tissue specific expression pattern. J
Biotechnol. 141:8–17. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Llacua LA, Hoek A, de Haan BJ and de Vos
P: Collagen type VI interaction improves human islet survival in
immunoisolating microcapsules for treatment of diabetes. Islets.
10:60–68. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lamandé SR and Bateman JF: Collagen VI
disorders: Insights on form and function in the extracellular
matrix and beyond. Matrix Biol. 71-72:348–367. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sato T, Takano R, Tokunaka K, Saiga K,
Tomura A, Sugihara H, Hayashi T, Imamura Y and Morita M: Type VI
collagen α1 chain polypeptide in non-triple helical form is an
alternative gene product of COL6A1. J Biochem. 164:173–181. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Åhrman E, Hallgren O, Malmström L,
Hedström U, Malmström A, Bjermer L, Zhou XH, Westergren-Thorsson G
and Malmström J: Quantitative proteomic characterization of the
lung extracellular matrix in chronic obstructive pulmonary disease
and idiopathic pulmonary fibrosis. J Proteomics. 189:23–33. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xin S, Fang W, Li J, Li D, Wang C, Huang
Q, Huang M, Zhuang W, Wang X and Chen L: Impact of STAT1
polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive
non-small cell lung cancer patients. J Cancer Res Clin Oncol.
147:725–737. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Blanco MA, LeRoy G, Khan Z, Alečković M,
Zee BM, Garcia BA and Kang Y: Global secretome analysis identifies
novel mediators of bone metastasis. Cell Res. 22:1339–1355. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Goldstraw P, Chansky K, Crowley J,
Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P,
Mitchell A, Bolejack V, et al: The IASLC lung cancer staging
project: Proposals for revision of the TNM stage groupings in the
forthcoming (Eighth) Edition of the TNM classification for lung
cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Akhurst T: Staging of non-small cell lung
cancer. PET Clin. 13:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
|
